Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cyclic guanosine monophosphate (cGMP) pathway is a critical intracellular signaling cascade in both animal and plant systems. cGMP itself is a cyclic nucleotide derived from guanosine triphosphate (GTP), acting as a second messenger that transduces signals from various extracellular stimuli to elicit diverse physiological responses. It regulates key processes such as smooth muscle relaxation, vasodilation, neurotransmission, gene expression, cell growth, apoptosis, and neural regeneration. Key components include guanylyl cyclases (sGC and pGC), nitric oxide synthase, phosphodiesterases (PDEs), and protein kinase G (PKG).
PDE5 inhibition increases cGMP levels leading to vasodilation and smooth muscle relaxation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic Guanosine Monophosphate Pathway.